Johnson & Johnson Q2 2026 Earnings: Pharma Strength Offsets STELARA Headwind, Guidance Raised
J&J posted $25.3B in Q2 2026 sales with 5.6% operational growth; strip out STELARA biosimilar erosion and the underlying business expanded double digits, prompting a full-year guidance raise.